Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment. [electronic resource]
Producer: 20200410Description: e481-e483 p. digitalISSN:- 1536-3678
- Adolescent
- Antineoplastic Agents -- therapeutic use
- Down Syndrome -- complications
- Humans
- Imatinib Mesylate -- therapeutic use
- Neoplasm Recurrence, Local -- drug therapy
- Oncogene Proteins, Fusion -- genetics
- Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases -- genetics
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Proto-Oncogene Proteins c-abl -- economics
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.